Clinical trial
Study of XL281 in Adults With Solid Tumors
NCT00451880 · Exelixis, Industry · Completed
Key facts
| NCT number | NCT00451880 |
|---|---|
| Title | Study of XL281 in Adults With Solid Tumors |
| Official title | A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors |
| Lead sponsor | Exelixis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma |
| Intervention type | Drug |
| Interventions | XL281, famotidine |
| Enrollment | 180 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Mar 26, 2007 |
| Last update posted | Oct 13, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: